Directori de persones
Antonia Salud Salvia

Antonia Salud Salvia

Grau: Doctor/a


masalud.lleida.ics(ELIMINAR)@gencat.cat

Grups

Publicacions

  • Valentí Moreno V; Brunet Vidal J; Manzano Alemany H; Salud Salvia A; Llobera Serentill M; Cabezas Montero I; Servitja Tormo S; Sopena Bert E; Gumà Padró J

    Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.

    CLINICAL & TRANSLATIONAL ONCOLOGY 8 208-212. .

  • Escudero, Pilar; Alonso, Vicente; Salud, Antonieta; Lambea, Julio; Valencia, Javier; Mira, Moises; Polo, Sonia; Lao, Juan; Sierra, E.; Anton, Antonio

    Preoperative radiochemotherapy with oxaliplatin and capecitabine in resectable rectal carcinoma: Preliminary results

    ANNALS OF ONCOLOGY 17 285-285. .

  • Munoz, Alberto; Salud, Antonieta; Garcia Giron, Carlos; Murias, Adolfo; Burillo, Miguel A.; Arizcun, Alberto; Gutierrez, David; Pujol, Eduardo

    Randomised phase III trial comparing irinotecan plus capecitabine (XELIRI Regimen) vs. irinotecan, 5-Fu and folinic acid (Saltz regimen) as first-line treatment in patients (PTS) with metastatic colorectal cancer (MCRC)

    ANNALS OF ONCOLOGY 17 120-120. .

  • Feliu, J; Castanon, C; Salud, A; Mel, JR; Escudero, P; Pelegrin, A; Lopez-Gomez, L; Ruiz, M; Gonzalez, E; Juarez, F; Lizon, J; Castro, J; Gonzalez-Baron, M; Oncopaz Cooperative Grp

    Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer

    BRITISH JOURNAL OF CANCER 93 1230-1235. .

    [doi:10.1038/sj.bjc.6602860]

  • Porcel, JM; Salud, A; Vives, M; Esquerda, A; Rodriguez-Panadero, F

    Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions.

    CLINICAL BIOCHEMISTRY 38 1031-1033. .

    [doi:10.1016/j.clinbiochem.2005.05.001]

  • Nogue, M; Salud, A; Batiste-Alentorn, E; Saigi, E; Losa, F; Cirera, L; Mendez, M; Campos, JM; Galan, A; Escudero, P; Arcusa, A; Manzano, H; de Mendizabal, EV; de Olaguer, JP; Boleda, M; Guasch, I; Vicente, P

    Randornised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer

    EUROPEAN JOURNAL OF CANCER 41 2241-2249. .

    [doi:10.1016/j.ejca.2005.07.013]

  • Salud, A.; Escudero, P.; Feliu, J.; Lopez-Gomez, L.; Bolanos, M.; Galan, A.; Yubero, A.; Vicent, J. M.; Losa, F.; Gonzalez-Baron, M.

    Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)

    Ejc Supplements 3 190-190. .

  • Alonso, V; Salud, A; Escudero, P; Bueso, P; Mira, M; Valencia, J; Polo, S; de Lobera, AR; Lao, J; Lastra, R

    Phase II trial of preoperative chemoradiotherapy with irinotecan and infusional 5-fluorouracil in locally advanced operable rectal carcinoma.

    Journal of Clinical Oncology 23 256-256. .

  • Saigi, E; Batiste-Alentorn, E; Diaz, N; Galan, A; Salud, A; Campos, JM; Losa, F; Gallen, M; Massuti, B; Asensio, D

    Phase II study of weekly irinotecan (CPT-11) associated to protracted oral tegafur (TGF) in previously untreated, advanced colorectal cancer (aCRC)

    Journal of Clinical Oncology 23 302-302. .

  • Salud, A; Escudero, P; Feliu, J; Lopez-Gomez, L; Bolanos, M; Galan, A; Yubero, A; Vicent, JM; Losa, F; Baron, MG

    XELOX (capecitabine and axaliplatin) as 1(st) line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC).

    Journal of Clinical Oncology 23 276-276. .

  • Hough, CL; Hudson, LD; Salud, A; Lahey, T; Curtis, JR

    Death rounds: end-of-life discussions among medical residents in the intensive care unit

    JOURNAL OF CRITICAL CARE 20 20-25. .

    [doi:10.1016/j.jcrc.2004.09.006]

  • Porcel, JM; Vives, M; Esquerda, A; Salud, A; Perez, B; Rodriguez-Panadero, F

    Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.

    Chest 126 1757-1763. .

    [doi:10.1378/chest.126.6.1757]

Projectes

  • Ajuts per a la contractació de personal investigador novell (FI)
  • Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
  • Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
  • UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante